
New chief executive for Biotec
pharmafile | February 12, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Biotec, UK, withey
Pharma supplies firm Biotec Services International has promoted Dr Fiona Withey to the position of chief executive.
Withey joined the UK-based firm’s business development team in 2007 after gaining a PhD in biochemical engineering from Swansea University, which was followed by 12 years working in the pharma outsourcing sector.
In 2008 Withey was appointed to the main board of directors as business development director. She played a large role in the company’s management buy-out in 2010 and since February 2012, she has headed up the operations team.
Withey replaces Keren Winmill who, after four years as chief executive of Biotec, is moving to the role of non-executive director and advisory board chair.
Withey said: “I’m delighted to be taking over the reins as chief executive. Keren has been an exceptional leader during the past four years; under her direction Biotec has become a world-renowned name for quality and flexibility in our industry.
Winmill added: “Fiona has a trusted reputation across the pharmaceutical industry. She will ensure the company continues to bring a combination of client focus, operational discipline and strong leadership to the team, I am very proud of everything that the team has accomplished during the past four years and I very much look forward to working with Fiona and the team on the next stage.”
Related Content

Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …

Digital Control Room, a major pharma provider, wins King’s Award for Enterprise
Buckingham Palace has announced that Digital Control Room, a software platform that monitors companies’ online …

Deadly cancers are being financially left behind, new research claims
New research has revealed that some of the UK’s most deadly and prevalent cancers receive …






